
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra Inc. is positioned for significant financial growth, supported by expectations of improving gross and operating margins, as well as above-average EPS growth relative to revenue increases. The company is projected to sustain mid-teens revenue growth over the next few years, with potential acceleration into the high-teens by 2026, driven by innovative product offerings and favorable market conditions. Additionally, Penumbra's leadership in the thrombectomy market, coupled with its anticipated neurovascular franchise expansion, underlines its attractiveness as a growth investment, especially as competition dynamics evolve.
Bears say
The analysis of Penumbra Inc. highlights several fundamental factors contributing to a negative outlook for the company's stock. Key concerns include potential setbacks in product launches, increased competition in the mechanical thrombectomy market, and the risk of unfavorable changes in reimbursement policies, all of which could adversely affect growth and revenue generation. Additionally, challenges in customer acquisition and dependency on successful regulatory approvals for new products further compound the uncertainties surrounding Penumbra's future financial performance.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares